The FDA has approved the POLARx Cryoablation System for treating paroxysmal atrial fibrillation. Meanwhile, Amneal Pharmaceuticals filed a New Drug Application for PEMRYDI RTU, aimed at non-squamous non-small cell lung cancer and malignant pleural mesothelioma. The global pleural diseases market is projected to grow, with thoracentesis expected to dominate treatment options, particularly in North America, driven by increasing healthcare investments and a rising geriatric population.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
